Sanofi India declares 12 percent growth in operating profits despite NLEM impact in Q2

The Company was largely able to maintain its gross margins, despite the NLEM impact. The Profit from Operations for the quarter were at INR 168 crores versus INR 150 crores in the previous year, i.e., a growth of 12% while the operating margins increased from 21.5% in Q2 2022 to 23.7% in Q2 2023. The improved operating margins were a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies.

The Company continues to make good progress on its ‘India for India’ strategy through go-to[1]market initiatives, improving operating efficiency and promoting innovation.

Read also: Sanofi-AstraZeneca Beyfortus gets unanimous US CDC Advisory Committee recommendation to prevent RSV in neonates, infants

Rodolfo Hrosz, Managing Director, Sanofi India Limited “The Company has delivered a strong second quarter performance despite the NLEM impact. The Company’s ‘India for India’ strategy reflects Sanofi’s ambition in the Indian Market. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India.”

Sanofi operates in India through two local entities, namely Sanofi India Limited and Sanofi Healthcare India Pvt. Limited. 

Read also: Sanofi India People Director Gaurav Bahadur resigns